Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer

Molecular Therapy

Volumn 12, Issue 5, 2005, Pages 942-949

  Li, Shulin ^a   Zhang, Lijie ^b   Torrero, Marina ^a   Cannon, Martin ^c   Barret, Robin ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Administration route; Electroporation; Electrotransfer; Gene therapy; IL 12; T cells

Indexed keywords

INTERLEUKIN 12;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NORTHERN BLOTTING; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TRANSGENE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; ELECTROPORATION; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; NEOPLASMS, SQUAMOUS CELL; PLASMIDS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

ANIMALIA;

EID: 27744538256     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.03.037     Document Type: Article

References (49)

1. G. Trinchieri Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes Blood 84 1994 4008-4027
2. F. Burke Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer Cytokines Cell. Mol. Ther. 5 1999 51-61
3. J. Golab and R. Zagozdzon Antitumor effects of interleukin-12 in pre-clinical and early clinical studies Int. J. Mol. Med. 3 1999 537-544
4. A.L. Rakhmilevich K. Janssen J. Turner J. Culp and N.S. Yang Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12 Hum. Gene Ther. 8 1997 1303-1311
5. Y. Watanabe et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity Proc. Natl. Acad. Sci. USA 86 1989 9456-9460
6. G. Colombo et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif J. Biol. Chem. 277 2002 47891-47897
7. S. Li and M. Benninger Applications of muscle electrotransfer gene therapy Curr. Gene Ther. 2 2002 101-105
8. C.S. Tannenbaum et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor J. Immunol. 161 1998 927-932
9. M.J. Brunda et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors J. Exp. Med. 178 1993 1223-1230
10. C.L. Nastala Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production J. Immunol. 153 1994 1697-1706
11. P. Lissoni F. Brivio S. Viviani and L. Fumagalli Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy? J. Biol. Regul. Homeostasis Agents 13 1999 110-114
12. W.K. Kang et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study Hum. Gene Ther. 12 2001 671-684
13. C.M. Divino et al. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells Breast Cancer Res. Treat. 60 2000 129-134
14. L.L. Worth S.F. Jia Z. Zhou L. Chen and E.S. Kleinerman Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases Clin. Cancer Res. 6 2000 3713-3718
15. R. Zhang and L.J. DeGroot Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model Clin. Endocrinol. (Oxford) 52 2000 687-694
16. J.L. Bramson et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 Hum. Gene Ther. 7 1996 1995-2002
17. L. Chen et al. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer J. Immunol. 159 1997 351-359
18. A.M. Davidoff S.A. Kimbrough C.Y. Ng S.J. Shochat and E.F. Vanin Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12 J. Pediatr. Surg. 34 1999 902-906
19. A. Gambotto et al. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12 Cancer Gene Ther. 6 1999 45-53
20. M. Yamamoto et al. In vivo gene electrotransfer of glial cell line-derived neurotrophic factor (GDNF) into skeletal muscle of SOD1 mutant mice Neurochem. Res. 26 2001 1201-1207
21. S. Li X. Zhang and X. Xia Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy J. Natl. Cancer Inst. 94 2002 762-768
22. M.J. Robertson et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer Clin. Cancer Res. 5 1999 9-16
23. J.P. Leonard et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production Blood 90 1997 2541-2548
24. U.M. Sarmiento et al. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri) Lab. Invest. 71 1994 862-873
25. J. Cohen IL-12 deaths: Explanation and a puzzle Science 270 1995 908
26. N.S. Tare et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen J. Interferon Cytokine Res. 15 1995 377-383
27. A.H. Rook et al. Interleukin-12 therapy of cutaneous T cell lymphoma induces lesion regression and cytotoxic T cell responses Blood 94 1999 902-908
28. Y. Sun et al. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study Gene Ther. 5 1998 481-490
29. M.K. Gately A.G. Wolitzky P.M. Quinn and R. Chizzonite Regulation of human cytolytic lymphocyte responses by interleukin-12 Cell Immunol. 143 1992 127-142
30. + T lymphocytes, and NK cells J. Immunol. 149 1992 3495-3502
31. + NK cells J. Immunol. 148 1992 2429-2436
32. G. Trinchieri Interleukin-12: A cytokine at the interface of inflammation and immunity Adv. Immunol. 70 1998 83-243
33. S.W. Dow et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases Hum. Gene Ther. 10 1999 2961-2972
34. I. Puisieux et al. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity Hum. Gene Ther. 9 1998 2481-2492
35. S. Li et al. Intramuscular electrotransfer delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site Gene Ther. 8 2001 400-407
36. S. Li X. Xia X. Zhang and J. Suen Regression of tumors by IFN-alpha electrotransfer gene therapy and analysis of the responsible genes by cDNA array Gene Ther. 9 2002 390-397
37. M. Coleman et al. Nonviral interferon alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response Hum. Gene Ther. 9 1998 2223-2230
38. E. Hanna et al. A novel alternative approach for prediction of radiation response of squamous cell carcinoma of head and neck Cancer Res. 61 2001 2376-2380
39. M.L. Lucas L. Heller D. Coppola and R. Heller IL-12 plasmid delivery by in vivo electrotransfer for the successful treatment of established subcutaneous B16.F10 melanoma Mol. Ther. 5 2002 668-675
40. R.J. Wong et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma Hum. Gene Ther. 12 2001 253-265
41. H.R. Marana J.M. Andrade and J.S. Silva Natural killer cells and interleukin-12 in patients with advanced cervical cancer under neoadjuvant chemotherapy Braz. J. Med. Biol. Res. 29 1996 473-477
42. M. Barajas et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 Hepatology 33 2001 52-61
43. C. Asselin-Paturel et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography Gene Ther. 6 1999 606-615
44. M.J. Lee et al. Optimal salt concentration of vehicle for plasmid DNA enhances gene transfer mediated by electrotransfer Exp. Mol. Med. 34 2002 265-272
45. K.J. Andrews et al. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells Cancer Res. 60 2000 6457-6464
46. K. Boggio et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice Cancer Res. 60 2000 359-364
47. S.J. Ha S.B. Lee C.M. Kim H.S. Shin and Y.C. Sung Rapid recruitment of macrophages in interleukin-12-mediated tumor regression Immunology 95 1998 156-163
48. E.A. Hirschowitz and R.G. Crystal Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases Am. J. Respir. Cell Mol. Biol. 20 1999 935-941
49. M.J. Brunda Role of IL12 as an anti-tumour agent: Current status and future directions Res. Immunol. 146 1995 622-628